Western blot data indicated that knocking down HER3 using HER3-specific siRNA resulted in significant reduction in p-ERK1/2 expression with no alteration in AKT pathway versus control in ovarian and colorectal cancer cell lines (Figure 8A–8D). The gene discussed is MAPK3; the disease is colorectal cancer.